{"filings":[{"id":1249438,"accession_number":"0000950103-26-009441","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2026-06-24T20:07:52+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Precigen stockholders approve 7M share increase for 2023 Omnibus Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; Randal Kirk received 207,060,147 votes for, 5,072,069 against.","Ratification of Deloitte & Touche as auditor: 272,813,907 for, 253,969 against.","Non-binding advisory say-on-pay approved: 208,241,739 for, 2,790,879 against.","2023 Plan Amendment No. 3 (7M additional shares) approved: 207,056,264 for, 4,996,260 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68723,"accession_number":"0000950103-26-007158","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2026-05-13T20:22:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.","Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025.","Patient hub enrollment reached ~400 patients; 25% from community settings.","Cash, equivalents, and investments totaled $56.7M as of March 31, 2026.","Permanent J-code (J3404) assigned effective April 1, 2026, expected to streamline access."],"consensus_eps_estimate":-0.0326,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":23252000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103207,"accession_number":"0000950103-26-004648","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen posts FY2025 net loss of $1.37/sh; PAPZIMEOS Q4 revenue $3.4M, launch momentum strong","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PAPZIMEOS generated $3.4M in net product revenue in Q4 2025, first partial quarter of US commercial sales.","Cash, cash equivalents, and investments $100.4M as of Dec 31, 2025, expected to fund to cash flow break-even.","Patient hub enrollment >300; payer coverage ~215M lives (~90% insured US); CMS assigned permanent J-code effective Apr 1, 2026.","Net loss attributable to common shareholders $429.6M ($1.37/sh) vs $126.2M ($0.47) in 2024, driven by non-cash warrant and preferred stock items.","R&D expenses down 22.1% YoY; SG&A up 69.8% reflecting commercial launch investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119444,"accession_number":"0000950103-25-014683","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Reports Q3 2025 Financial Results; PAPZIMEOS Full FDA Approval in August","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PAPZIMEOS (zopapogene imadenovec-drba) received full FDA approval in August 2025 for adults with RRP.","Over 100 patients registered in PAPZIMEOS Patient Hub; more than 100 million lives covered by private insurance.","Submitted Marketing Authorization Application to EMA for zopapogene imadenovec in November 2025.","Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025.","Entered credit facility providing up to $125 million non-dilutive financing; received first tranche of $100 million."],"consensus_eps_estimate":-0.0969,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136003,"accession_number":"0000950103-25-011775","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Precigen: $79M Preferred Stock converted into 54.9M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders converted 79,000 shares of 8.00% Series A Convertible Preferred Stock (stated value $79M) into 54,937,411 common shares.","Conversion rate: 695.4103 common shares per $1,000 of Preferred Stock stated value, delivered on Sept 17, 2025.","Shares issued in reliance on Section 3(a)(9) exemption; no commission paid.","Conversion increases common share count by ~54.9M, potentially dilutive to existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136002,"accession_number":"0001104659-25-086669","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Precigen secures up to $125M non-dilutive senior secured loan financing from Pharmakon","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M funded at close; $25M delayed draw available through June 2027; matures Sept 2030.","Interest at three-month SOFR (3.75% floor) + 6.50%, payable quarterly; amortization begins Sept 2028.","Proceeds to support U.S. commercialization of PAPZIMEOS and potential expansion into international and pediatric indications.","Loan is senior secured by substantially all U.S. assets, including IP; customary covenants and events of default.","CFO states strengthening balance sheet provides financial flexibility as company enters projected significant growth period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136001,"accession_number":"0001104659-25-079497","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Precigen announces FDA approval of PAPZIMEOS (no further details)","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["US FDA approval of PAPZIMEOS announced via slide deck at August 18, 2025 investor webcast.","No additional specifics such as indication or market size provided in this filing.","The approval represents a significant regulatory milestone for Precigen (PGEN)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136000,"accession_number":"0000950103-25-010408","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Precigen enters into commercial supply agreement with Catalent for PAPIZEMOS manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement dated August 13, 2025 with Catalent Maryland for fill/finish services for gene therapy PAPIZEMOS (PRGN-2012).","Precigen grants Catalent exclusive rights for external commercial fill/finish manufacturing of the product in the Territory.","Initial term of three years, automatically renews annually unless 12-month termination notice given.","Precigen commits to minimum batch purchases per contract year as specified in the Plan Document.","Pricing subject to annual adjustment based on labor, utilities, and overhead costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153043,"accession_number":"0000950103-25-008124","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Precigen shareholders approve 300M share increase, re-elect directors, and expand equity plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased authorized common shares by 300 million (223.2M votes for).","Randal J. Kirk approved to receive Series A Preferred Stock and Warrants as PIK dividends (167.4M for).","2023 Omnibus Incentive Plan expanded by 11.5M shares; 2019 Non-Employee Plan expanded by 1.1M shares.","All nine director nominees elected; top vote-getter Helen Sabzevari with 177.9M votes.","Deloitte ratified as auditor (228.9M for); advisory say-on-pay passed (175.9M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153042,"accession_number":"0000950103-25-006004","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q1 net loss $54.2M; PRGN-2012 BLA under FDA priority review with PDUFA Aug 27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $54.2M ($0.18/share) vs $23.7M ($0.10) YoY; includes $32.5M non-cash warrant liability fair value change.","Cash and investments $81.0M as of March 31, 2025; Q1 cash burn $16.9M; runway into 2026.","BLA for PRGN-2012 (RRP) under FDA priority review; PDUFA target action date August 27, 2025.","Pivotal study: 51% complete response, 86% reduction in surgeries; median follow-up 30 months.","Selected EVERSANA for commercialization support; advancing launch readiness for potential 2025 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1341000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171821,"accession_number":"0000950103-25-003637","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen reports FY2024 net loss of $126M; FDA priority review for PRGN-2012 BLA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for PRGN-2012 with priority review; PDUFA target date Aug 27, 2025.","Pivotal study: 51% complete response (no surgeries), durable beyond 12 months (median 24 months).","FY2024 net loss $126.2M ($0.47/share) vs $95.9M in 2023; revenue down 37% to $3.9M.","Cash, equivalents, investments $97.9M; runway extended into 2026 beyond potential launch.","Raised $87.5M in Dec 2024 from convertible preferred stock ($79M) and IP/royalty sale ($8.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171820,"accession_number":"0000950103-25-000576","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Precigen regains Nasdaq bid price compliance, delisting risk resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Precigen on Jan 16, 2025 that it regained compliance with the $1.00 minimum bid price rule.","Stock closed at or above $1.00 for 10 consecutive business days from Dec 31, 2024 to Jan 15, 2025.","This resolves the deficiency first disclosed on Nov 1, 2024; the matter is closed.","No further action needed; company avoids potential delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188827,"accession_number":"0000950103-24-018479","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.01","8.01","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Precigen completes BLA submission for PRGN-2012 and raises $79M in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Submitted BLA to FDA for PRGN-2012 (RRP), requesting priority review; 60-day review period to determine acceptance.","Phase 1/2 pivotal study: >50% of patients achieved Complete Response; >85% had fewer surgeries in year post-treatment.","Raised $79M gross from sale of 8% Series A Convertible Perpetual Preferred Stock and warrants to purchase 52.7M shares at $0.75.","Investors include Randal Kirk, Patient Capital Management, Bill Miller; proceeds for working capital and general corporate purposes.","Cash runway extends into 2026, beyond potential commercial launch in H2 2025 if PRGN-2012 is approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188826,"accession_number":"0000950103-24-018350","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Precigen sells FCX-007 assets for $8.5M cash, exits Castle Creek collaboration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset Acquisition Agreement with Innovator 21 (Paragon affiliate) closed Dec 24, 2024 for $8.5M cash.","Sold IP and royalty rights related to FCX-007, a clinical-stage candidate for Epidermolysis Bullosa.","Precigen has no further rights or obligations to Castle Creek or retained product royalties.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188825,"accession_number":"0000950103-24-016317","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q3 net loss widens to $24M; on track for Q4 PRGN-2012 BLA submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.0M ($0.09/sh) vs $19.8M loss YoY; nine-month loss $106.5M ($0.41/sh).","Completed pre-BLA meeting with FDA; full alignment on BLA content for PRGN-2012 in RRP; rolling submission planned Q4 2024.","Commercial and manufacturing readiness underway for potential 2025 launch of PRGN-2012.","Confirmatory trial for PRGN-2012 initiated; end of Phase 1b meeting for PRGN-3006 in AML expected early 2025.","August 2024 equity offering raised net $30.9M; workforce reduced by over 20%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188824,"accession_number":"0000950103-24-016076","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Precigen receives Nasdaq bid price deficiency notice; has until Apr 30, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $1 for 30 consecutive business days; compliance deadline April 30, 2025.","To regain compliance, bid price must close at $1+ for at least 10 consecutive business days.","If not compliant by deadline, may qualify for additional 180-day period if transferred to Nasdaq Capital Market and meets other standards.","Company may consider reverse stock split to cure deficiency; no assurance of compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188823,"accession_number":"0000950103-24-014811","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Precigen terminates Alaunos license agreement, regains all rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Amended and Restated License Agreement with Alaunos effective Oct 4, 2024.","Precigen regains all rights previously licensed to Alaunos under the agreement.","Alaunos retains no rights to use any Precigen technology.","Original A&R License Agreement was entered into on April 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205306,"accession_number":"0000950103-24-013816","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Precigen SVP of Intellectual Property Affairs Jeffrey Perez to depart Nov 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Perez, SVP of Intellectual Property Affairs, will separate from Precigen effective November 1, 2024.","Perez is expected to remain in his current role through the separation date for transition purposes.","Severance payments and benefits will be provided under his existing employment agreement dated April 2, 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205305,"accession_number":"0000950103-24-012981","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Precigen grants PSUs tied to PRGN-2012 BLA milestones to named execs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Target PSUs granted: CEO Helen Sabzevari 1,650,000; CFO Harry Thomasian 250,000; COO Rutul Shah 250,000; CLO Donald Lehr 108,000.","Vesting in two 50% installments upon: (1) FDA submission of BLA for PRGN-2012, (2) FDA approval of BLA, both by Dec 31, 2026.","PSUs forfeited if milestones not achieved by end of Performance Period; vesting accelerated upon change in control in certain cases.","Pro-rata vesting applies on termination without cause or for good reason; full forfeiture on other termination events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205304,"accession_number":"0000950103-24-012201","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q2 net loss widens to $58.8M; pivots to PRGN-2012 with BLA submission planned H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss of $58.8M ($0.23/share) vs $20.3M loss a year ago; includes impairment charge of $32.9M.","Total revenues fell 59% YoY to approx $0.8M; R&D expenses rose 32% on severance and PRGN-2012 trial costs.","Strategic reprioritization focuses on PRGN-2012 BLA submission under accelerated path H2 2024; workforce reduced >20%.","Appointed Phil Tennant as CCO for potential PRGN-2012 commercial launch; raised $31.4M net in August public offering.","Cash runway expected into early 2025; ActoBio subsidiary shut down, IP portfolio available for sale."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205303,"accession_number":"0001104659-24-087596","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Precigen raises ~$31.4M net in underwritten public offering of 35.3M shares at $0.85","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Precigen entered into underwriting agreement with Stifel for offering of 35,294,118 shares at $0.85/share.","Underwriters have 30-day option for up to 5,294,117 additional shares; 4,584,821 shares exercised.","Net proceeds approximately $31.4 million after underwriting discounts and estimated expenses.","Offering made under shelf registration statement declared effective January 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205302,"accession_number":"0001104659-24-086275","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Precigen reports $19.5M cash, $32.9M impairment, $30M offering, >20% workforce cut","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash $19.5M at June 30, 2024; non-cash impairment charges ~$32.9M and severance ~$3.0M in Q2/Q3.","Strategic pivot to PRGN-2012 gene therapy; rolling BLA submission expected H2 2024; ActoBio subsidiary shutdown.","Commences $30M underwritten public offering (plus $4.5M option); expects net proceeds plus cash to fund ops into early 2025.","Workforce reduced >20%; PRGN-2009 non-NCI sites paused; UltraCAR-T programs paused except PRGN-3006; preclinical halted.","PRGN-2012 confirmatory trial initiated; commercial readiness led by new CCO; revenue not reported (pre-revenue stage)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205301,"accession_number":"0000950103-24-009693","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Precigen elects Nancy Howell Agee to board; shareholders approve 2M share increase in incentive plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dean Mitchell's term ended July 5, 2024; he did not stand for re-election, no disagreement cited.","Nancy Howell Agee elected to the board effective July 5, 2024.","Shareholders approved amendment to 2023 Omnibus Incentive Plan increasing shares available by 2,000,000.","All director nominees elected with majority support; Deloitte & Touche ratified as auditor; say-on-pay passed.","Vote results: Randal Kirk received 146,479,803 for; other directors similarly elected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222192,"accession_number":"0000950103-24-006675","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q1 net loss $23.7M, revenue down 43%; PRGN-2012 BLA submission on track for H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.7M ($0.10 EPS) vs $22.7M; total revenue down 43% YoY to approx. $1.06M.","Cash, equivalents, and short-term investments $44.8M; evaluating financing options to strengthen balance sheet.","PRGN-2012 pivotal Phase 2 data as late-breaking oral at ASCO June 3; rolling BLA submission expected H2 2024.","Commercial readiness activities underway for potential PRGN-2012 launch in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241709,"accession_number":"0000950103-24-004017","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen reports FY2023 loss of $95.9M; plans BLA submission for PRGN-2012 in H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $6.2M, down 77% YoY; net loss $95.9M ($0.39 loss per share).","Cash and investments $62.9M; SG&A down 16% to support cost containment.","Plans to submit BLA for PRGN-2012 under accelerated approval in H2 2024; potential launch 2025.","PRGN-2009 IND cleared Phase 2 in cervical cancer; interim data for PRGN-3006 and PRGN-3007 expected H2 2024.","Recorded $10.4M goodwill impairment charge for Exemplar subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241708,"accession_number":"0000950103-24-001932","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Precigen enters continuing employment agreements with CFO and COO providing 12-month severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Harry Thomasian Jr. and COO Rutul R. Shah entered continuing employment agreements approved Feb 2, 2024.","Severance payment equals 12 months base pay upon termination without cause or for good reason.","Company will cover COBRA premiums for up to 12 months following qualifying termination.","Agreements are substantially similar to those for other named executive officers (excluding CEO)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241707,"accession_number":"0000950103-24-000379","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Precigen announces PRGN-2012 Phase 2 data expected Q2 2024; BLA submission planned H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRGN-2012 Phase 2 pivotal data in RRP anticipated Q2 2024; BLA submission under accelerated approval H2 2024.","Commercial readiness preparations underway for potential PRGN-2012 launch in 2025.","PRGN-2009 Phase 2 study in OPSCC enrolling; cervical cancer trial to start Q1 2024.","PRGN-3006 Phase 1b dose expansion interim data expected H2 2024; Phase 1 showed 27% ORR in r/r AML.","New CD19 UltraCAR-T preclinical data presented; Phase 1 study preparation underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259163,"accession_number":"0000950103-23-016146","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q3 2023 loss per share $0.08; FDA agrees PRGN-2012 study pivotal for BLA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $79.0M as of Sep 30, 2023; cash runway projected into 2025.","Total revenues decreased 92% to $1.3M in Q3 2023 from $16.6M in Q3 2022, largely from prior-year non-cash collaboration revenue.","Loss from continuing operations $19.8M ($0.08 per share) vs. $7.6M ($0.04) in Q3 2022.","FDA agreed ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as pivotal for accelerated BLA; Phase 2 enrollment complete, expected completion Q2 2024.","SG&A costs down 9% in Q3 and 17% for first nine months 2023 vs. prior year, driven by reduced professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276427,"accession_number":"0000950103-23-011755","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"FDA confirms PRGN-2012 Phase 1/2 study as pivotal for accelerated approval; cash runway into 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed ongoing Phase 1/2 single-arm study of PRGN-2012 for RRP as pivotal for accelerated approval; no placebo trial needed.","Retired all outstanding convertible notes in Q2; cash, equivalents, and investments totaled $95.6M as of June 30, 2023.","Q2 2023 loss from continuing operations was $20.3M ($0.08/share), improved from $26.1M loss in Q2 2022.","SG&A expenses decreased 27% Q2 vs prior year; revenue fell 39% due to reduced services at Exemplar.","Projected cash runway into 2025; Phase 2 enrollment complete, data collection by Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294152,"accession_number":"0000950103-23-008709","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Precigen shareholders approve 2023 Omnibus Incentive Plan at Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; Randal Kirk received 146.7M votes for.","Deloitte & Touche ratified as auditor for FY2023 (187.1M votes for).","Non-binding advisory say-on-pay resolution approved (142.9M votes for).","2023 Omnibus Incentive Plan approved: 12.5M new shares plus carryover from 2013 Plan (145.4M votes for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294151,"accession_number":"0000950103-23-007072","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q1 loss narrows to $22.7M; raises $72.8M in offering; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 66% YoY; Q1 operating loss $22.7M ($0.10 EPS) vs $23.9M ($0.12 EPS) in Q1 2022.","Cash, equivalents and investments $125.4M; net proceeds of $72.8M from public offering at $1.75/share.","Retired $29.5M of convertible notes; remaining $13.8M due July 2023 to be retired with restricted cash.","Phase 1 PRGN-2012 data: 50% complete response; Phase 2 enrollment completed (N=23).","First patient dosed with PRGN-3007 UltraCAR-T (PD-1 checkpoint); regained exclusive rights to CD19 and BCMA targets."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":1851000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294150,"accession_number":"0000950103-23-005425","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Precigen enters amended license with Alaunos for TCR products; Alaunos pays $75K annual fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Precigen grants Alaunos exclusive, worldwide, royalty-free license for T-cell receptor products targeting neoantigens and HPV.","Alaunos also gets exclusive license for Sleeping Beauty technology for TCR products for neoantigens and shared antigens.","Alaunos pays $75,000 annual license fee; no milestones or royalties on products.","Alaunos loses rights to IL-12, CAR (CD-19, BCMA), and Gorilla IL-12 products; Precigen retains those.","Precigen may develop products outside the exclusive license; Alaunos can terminate on country/program basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314762,"accession_number":"0000950103-23-003966","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Precigen reports minimal SVB exposure, reaffirms cash runway into late 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company has minimal exposure to Silicon Valley Bank after its closure and FDIC receivership.","Reaffirms that cash, cash equivalents, and short-term investments will fund clinical priorities into late 2024.","No financial or operational impact from SVB failure is expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314761,"accession_number":"0000950103-23-003720","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen reports Q4 2022 loss of $22.2M; cash $99.7M; clinical progress in RRP and AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 loss from continuing ops $22.2M ($0.11/sh); full year loss $79.8M ($0.40/sh).","Cash, equivalents, short-term investments, restricted cash $99.7M as of Dec 31, 2022.","Divested Trans Ova Genetics for $162.3M net; retired $156.7M of convertible notes in 2022.","Jan 2023 public offering raised ~$73M net from 44M shares at $1.75/sh.","Positive Phase 1 data: PRGN-2012 in RRP (50% complete response) and PRGN-3006 in AML (27% ORR)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314760,"accession_number":"0001104659-23-007269","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Precigen (PGEN) prices public offering of 42.9M shares at $1.75, net ~$71.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriting agreement with J.P. Morgan Securities as lead for 42,857,143 firm shares at $1.75/share.","Underwriters have 30-day option to purchase up to 6,428,571 additional shares.","Net proceeds of approximately $71.2 million after underwriting discount and expenses.","Offering made under existing shelf registration; use of proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314759,"accession_number":"0001104659-23-006194","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Precigen reports positive Phase 1 PRGN-2012 data: 50% complete response in RRP patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50% of RRP patients at Dose Level 2 achieved Complete Response, requiring no post-treatment surgeries.","Median annual RRP surgeries dropped from 6.5 pre-treatment to 0.5 post-treatment at Dose Level 2.","PRGN-2012 well-tolerated with no dose-limiting toxicities and no treatment-related Grade ≥3 adverse events.","Preliminary cash, equivalents, and investments totaled ~$56M as of Dec 31, 2022; restricted cash ~$43.7M.","Phase 2 study enrolling; 32 patients enrolled at Dose Level 2 to date; FDA discussions advancing for regulatory strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314758,"accession_number":"0000950103-23-000404","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Precigen reports pipeline progress and R&D Day for PRGN-2012 data on Jan 24, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRGN-2012 Phase 2 enrollment rapid; 20 patients enrolled; R&D Day Jan 24 to share Phase 1 data.","PRGN-2009 Phase 2 monotherapy arm near full enrollment: 19 of 20 patients; interim data expected H2 2023.","PRGN-3006 in AML: Phase 1 dose escalation data presented at ASH; Phase 1b expansion includes Mayo Clinic; first repeat dose cleared.","PRGN-3005 in ovarian cancer: Phase 1 dose escalation completed; first repeat dose given; expansion enrollment ongoing.","PRGN-3007 (next-gen UltraCAR-T) trial open for enrollment; first patient dosing expected Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333155,"accession_number":"0000950103-22-019454","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q3 net loss $7.6M; cash $153.8M; retired $144M convertible notes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $7.6M ($0.04/sh) vs $26.3M loss; total revenues up $13.4M (>200%) YoY.","Cash, equivalents, short-term investments and restricted cash totaled $153.8M as of Sep 30, 2022.","Retired $144M of $200M convertible notes due July 2023 at a discount; realized $5.4M savings.","Clinical: Phase 1 enrollment complete for PRGN-2012 in RRP; virtual R&D event Jan 2023; ASH presentations.","Phase 1b expansion for PRGN-3006 at Mayo Clinic; first patient dosed; FDA clearance for repeat dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":25146000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350617,"accession_number":"0000950103-22-016191","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-09-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Precigen appoints Rutul R. Shah as COO, effective Oct 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rutul R. Shah, previously VP Head of Operations, appointed COO; newly created role.","Base salary increased from $300K to $410K; no other compensation changes disclosed.","Shah brings 17+ years biopharma experience, 8 focused on gene and cell therapies.","New COO will oversee strategic portfolio management and operational efficiency.","Shah will report to President and CEO Helen Sabzevari and join leadership team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350611,"accession_number":"0000950103-22-014407","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K/A","filed_at":"2022-08-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Precigen completes $170M sale of Trans Ova Genetics; pro forma shows $213M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of 100% of Trans Ova to Spring Bidco LLC for $170M; net cash proceeds ~$169.5M.","Pro forma cash and equivalents rise to $213.4M from $43.8M as of June 30, 2022.","Pro forma continuing ops loss of $49.2M for H1 2022 vs. historical loss of $36.9M (net of discontinued ops).","Pro forma continuing ops loss of $110.8M for FY2021, compared to historical net loss of $96.8M.","Pro forma balance sheet eliminates $88.9M of assets and $15.1M of liabilities classified as held for sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350616,"accession_number":"0000950103-22-014273","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-08-22T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Precigen completes sale of Trans Ova Genetics for $170M upfront plus up to $10M earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed on August 18, 2022; buyer is Spring Bidco LLC (URUS). Net proceeds ~$169.5M after adjustments.","Company plans to use $200M (including proceeds) to pay senior convertible notes and for other permitted purposes.","Up to $10M earn-out based on Trans Ova performance in 2022-2023, payable in cash.","Divestiture allows Precigen to focus on its core gene and cell therapy pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350615,"accession_number":"0000950103-22-013822","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Precigen enters $100M ATM equity offering with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $100M of common stock may be sold at-the-market through Cantor Fitzgerald as agent.","Commission of 3.0% of gross sales price payable to Cantor Fitzgerald.","Proceeds to fund clinical/preclinical development and for working capital and general corporate purposes.","Company has no obligation to sell any shares; may suspend or terminate at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350614,"accession_number":"0000950103-22-013773","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q2 loss from cont. ops $26.1M; divests Trans Ova Genetics for $170M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Loss from continuing ops $26.1M ($0.13 loss per share) vs $30.9M loss in Q2 2021.","Total revenues down 24% YoY; SG&A decreased 15%.","Agreed to sell Trans Ova Genetics to URUS for $170M cash upfront plus up to $10M earn-out; close expected Q3 2022.","Cash and investments $132.8M as of June 30, 2022; proceeds intended to pay convertible notes due July 2023.","Believes cash plus cost reductions provide runway into Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":8424000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350613,"accession_number":"0000950103-22-012319","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-07-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Precigen wins arbitration, to acquire membership interests for $7M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arbitration panel adopted Precigen's proposed terms for disputes with investors in Intrexon Energy Partners entities.","Precigen to acquire investors' membership interests for approx. $7 million in cash.","Panel was required to choose one of two proposals without compromise; chose Precigen's.","Ruling resolves previously disclosed pending arbitration matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350612,"accession_number":"0000950103-22-011927","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-07-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Precigen agrees to sell Trans Ova Genetics to URUS for $170M upfront cash plus $10M earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $180M: $170M cash at closing plus $10M earn-out based on 2022-2023 performance.","Transaction expected to close in Q3 2022, subject to HSR clearance and other customary conditions.","Proceeds will be used to pay senior convertible notes due July 2023 and fund healthcare pipeline.","Divestiture completes strategy to focus exclusively on healthcare, shedding the animal reproductive technologies unit.","Rabo Securities acted as financial advisor; Davis Polk provided legal support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367800,"accession_number":"0000950103-22-010571","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Precigen shareholders elect all directors, approve equity plan amendments at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Helen Sabzevari top vote-getter with 121.2M votes.","Say-on-pay passed with 95.3M for (77% of votes cast); 26.6M against (22%).","Amendment to 2013 Omnibus Incentive Plan approved, adding 10M shares to reserve.","Amendment to 2019 Non-Employee Service Provider Plan approved, adding 7M shares.","Ratification of Deloitte & Touche as independent auditor for FY2022 passed (154.9M for, 97.3%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367799,"accession_number":"0000950103-22-008134","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q1 revenue $32M (+31% YoY); Fast Track for PRGN-3006 in AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $32.0M, up 31% vs $24.5M YoY; net loss $19.3M ($0.10/share).","Cash, equivalents, short- & long-term investments $142.1M as of March 31, 2022.","FDA Fast Track designation for PRGN-3006 UltraCAR-T in relapsed/refractory AML.","Phase 2 study for PRGN-2012 in RRP dosed first patient; Phase 1b expansion arm for PRGN-3006 initiated.","R&D expenses rose $2.2M (+21%) driven by clinical/preclinical program advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":32021000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387145,"accession_number":"0000950103-22-003581","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q4 net loss $25M, FY loss $96.8M; $163.7M cash; clinical progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss from continuing ops $25.0M ($0.13/sh) vs $39.7M ($0.22/sh) year ago; full-year net loss $96.8M ($0.49/sh) vs $103.8M.","Cash, cash equivalents and investments totaled $163.7M as of Dec 31, 2021; net cash used in ops $55.8M in 2021, down from $77.0M in 2020.","January 2021 public offering of 17.25M shares raised gross proceeds of ~$129.4M; cash expected to fund operations well into 2023.","Clinical milestones: completed enrollment in PRGN-3006 AML, PRGN-3005 ovarian, and PRGN-2012 RRP studies; IND clearances for PRGN-3007 and PRGN-2012.","R&D expenses up 20% for the year; SG&A down 19%; non-core businesses (Trans Ova, Exemplar) increased revenues and profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":103873000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405079,"accession_number":"0000950103-21-017355","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Precigen reports Phase 1 data: 50% AML ORR, 40% HPV ORR; cash $181.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50% ORR (3/6) in relapsed/refractory AML at low dose levels of PRGN-3006 UltraCAR-T in Phase 1 lymphodepletion cohort.","40% ORR (2/5) and 60% DCR (3/5) in recurrent/metastatic HPV-associated cancer with PRGN-2009 AdenoVerse combination arm.","PRGN-3006 and PRGN-3005 show no dose-limiting toxicities or neurotoxicity; durable expansion and persistence observed.","Cash, equivalents, and investments totaled $181.3M at Sep 30, 2021; net cash used in ops $41.2M (9 months, vs $60.6M prior year).","PRGN-3006 abstract selected for oral presentation at 63rd ASH Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405078,"accession_number":"0000950103-21-015724","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2021-10-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Precigen appoints Harry Thomasian Jr. as CFO effective Oct 18, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harry Thomasian Jr., 59, appointed CFO, effective October 18, 2021; succeeds interim CFO James V. Lambert.","Thomasian previously a partner at EY for 19 years, life sciences and capital markets experience.","Compensation: base salary $440,000.16, target annual bonus 40% of base, stock options for 180,000 shares vesting over 4 years.","Appointment fills CFO role vacant since Rick Sterling resigned April 2021; search completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-10-12T23:59:59+00:00|405078"}